| scholarly article | Q13442814 |
| P50 | author | Alessio Fasano | Q18686101 |
| Marcela F. Pasetti | Q56380831 | ||
| Karen L Kotloff | Q63214788 | ||
| Myron M. Levine | Q29564379 | ||
| P2093 | author name string | Marcelo B Sztein | |
| Eileen M Barry | |||
| P2860 | cites work | Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine | Q21245322 |
| Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection | Q73292613 | ||
| Experimental shigella keratoconjunctivitis; a preliminary report | Q78714396 | ||
| Receptor mediated targeting of M-cells | Q79717125 | ||
| Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media | Q81445405 | ||
| The human gut microbiota and undernutrition | Q84313779 | ||
| Genetic characteristics and changing antimicrobial resistance among Shigella spp. isolated from hospitalized diarrhoeal patients in Kolkata, India | Q84322615 | ||
| Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers | Q84554549 | ||
| Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine | Q84592118 | ||
| Wide dissemination of multidrug-resistant Shigella isolates in China | Q84806742 | ||
| Salmonella, Campylobacter and Shigella in HIV-seropositive patients | Q50170347 | ||
| The role of Shigella spp., enteroinvasive Escherichia coli, and other enteropathogens as causes of childhood dysentery in Thailand | Q50203316 | ||
| Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. | Q50464343 | ||
| Efficacy of oral poliovirus vaccine in rural communities of North Arcot District, India. | Q50552425 | ||
| Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh. | Q51745561 | ||
| New animal model of shigellosis in the Guinea pig: its usefulness for protective efficacy studies. | Q53579124 | ||
| Vaccine potential for inactivated shigellae. | Q53581992 | ||
| A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. | Q54158784 | ||
| Cephalosporin-resistant Shigella flexneri over 9 years (2001-09) in India. | Q54319602 | ||
| Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. | Q54572055 | ||
| Prevalence of Shigella Enterotoxin 1 among Shigella Clinical Isolates of Diverse Serotypes | Q54601009 | ||
| Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis. | Q55052109 | ||
| Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants | Q57530944 | ||
| Changing species distribution and antimicrobial susceptibility pattern of Shigella over a 29-year period (1980-2008) | Q57935892 | ||
| Delayed and reduced adaptive humoral immune responses in children with shigellosis compared with in adults | Q57939911 | ||
| Disease-dependent changes in T-cell populations in patients with shigellosis | Q57940370 | ||
| Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. | Q64948328 | ||
| Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei | Q67941446 | ||
| Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population | Q68134308 | ||
| Age-Specific Prevalence of Serum Antibodies to the Invasion Plasmid and Lipopolysaccharide Antigens of Shigella Species in Chilean and North American Populations | Q68159705 | ||
| Convulsions in childhood shigellosis. Clinical and laboratory features in 153 children | Q68932658 | ||
| Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model | Q70573636 | ||
| The response of man to virulent Shigella flexneri 2a | Q72377709 | ||
| Serum IgG antibody responses to Shigella invasion plasmid-coded antigens detected by immunoblot | Q72868569 | ||
| Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T | Q22065494 | ||
| Genome dynamics and diversity of Shigella species, the etiologic agents of bacillary dysentery | Q22065981 | ||
| Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157 | Q22065995 | ||
| Production of glycoprotein vaccines in Escherichia coli | Q24628546 | ||
| ShiBASE: an integrated database for comparative genomics of Shigella | Q25257766 | ||
| High yield production process for Shigella outer membrane particles | Q28728768 | ||
| Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate. | Q30369367 | ||
| Diagnostic microbiologic methods in the GEMS-1 case/control study | Q30423347 | ||
| Serine protease autotransporters from Shigella flexneri and pathogenic Escherichia coli target a broad range of leukocyte glycoproteins | Q30431075 | ||
| Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. | Q30448313 | ||
| Immunoproteomics of membrane proteins of Shigella flexneri 2a 2457T. | Q33232135 | ||
| Shigella septicemia: prevalence, presentation, risk factors, and outcome. | Q33460343 | ||
| Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes | Q33478268 | ||
| A changing picture of shigellosis in southern Vietnam: shifting species dominance, antimicrobial susceptibility and clinical presentation | Q33518017 | ||
| Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants | Q33557800 | ||
| Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoid | Q33607442 | ||
| Effect of shigella enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivo | Q33617990 | ||
| A challenge model for Shigella dysenteriae 1 in cynomolgus monkeys (Macaca fascicularis). | Q33676706 | ||
| Global burden of Shigella infections: implications for vaccine development and implementation of control strategies | Q33749510 | ||
| Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602 | Q33876803 | ||
| Outer membrane protein A (OmpA) of Shigella flexneri 2a, induces protective immune response in a mouse model | Q33983350 | ||
| Strategy for cross-protection among Shigella flexneri serotypes | Q34000330 | ||
| Characterization of pic, a secreted protease of Shigella flexneri and enteroaggregative Escherichia coli. | Q34002298 | ||
| The sigA gene which is borne on the she pathogenicity island of Shigella flexneri 2a encodes an exported cytopathic protease involved in intestinal fluid accumulation. | Q34004127 | ||
| Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults | Q34120926 | ||
| Regulation of the overlapping pic/set locus in Shigella flexneri and enteroaggregative Escherichia coli | Q34122666 | ||
| Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference | Q34207204 | ||
| Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro | Q34224319 | ||
| Functional comparison of serine protease autotransporters of enterobacteriaceae | Q34262034 | ||
| Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity | Q34394744 | ||
| Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. | Q39146446 | ||
| Concentration of milk secretory immunoglobulin A against Shigella virulence plasmid-associated antigens as a predictor of symptom status in Shigella-infected breast-fed infants | Q39232647 | ||
| Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile | Q39252440 | ||
| Further characterization of Shigella sonnei live vaccine candidates WRSs2 and WRSs3-plasmid composition, invasion assays and Sereny reactions | Q39461241 | ||
| Shigella enterotoxin-2 is a type III effector that participates in Shigella-induced interleukin 8 secretion by epithelial cells | Q39610195 | ||
| Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine | Q39655324 | ||
| Shigella infection induces cellular activation of T and B cells and distinct species-related changes in peripheral blood lymphocyte subsets during the course of the disease | Q39822623 | ||
| Changes in the peripheral blood T-Cell receptor V beta repertoire in vivo and in vitro during shigellosis. | Q39824716 | ||
| Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a. | Q40123700 | ||
| Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis | Q40211202 | ||
| Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. | Q40460000 | ||
| Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. | Q40469794 | ||
| Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial | Q40501431 | ||
| Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children | Q40552513 | ||
| Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2 | Q40687041 | ||
| Clinical trials of Shigella vaccines in Israel. | Q41041423 | ||
| Protection against keratoconjunctivitis shigellosa induced by immunization with outer membrane proteins of Shigella spp. | Q41186719 | ||
| Developing live Shigella vaccines using lambda Red recombineering | Q41452880 | ||
| Short report: high prevalence of serine protease autotransporter cytotoxins among strains of enteroaggregative Escherichia coli. | Q42072861 | ||
| Studies on vaccination against bacillary dysentery. 3. Effective oral immunization against Shigella flexneri 2a in a field trial | Q42982958 | ||
| Health status of displaced persons following Civil War--Burundi, December 1993-January 1994. | Q43327903 | ||
| Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection. | Q43432983 | ||
| A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection | Q43461979 | ||
| Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand | Q43649055 | ||
| Structural elucidation of the O-antigen of the Shigella flexneri provisional serotype 88-893: structural and serological similarities with S. flexneri provisional serotype Y394 (1c). | Q43859842 | ||
| Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates | Q46354821 | ||
| Pathogenesis of Shigella dysenteriae 1 (Shiga) Dysentery | Q46613719 | ||
| Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine | Q46902186 | ||
| SepA, the 110 kDa protein secreted by Shigella flexneri: two-domain structure and proteolytic activity | Q47721067 | ||
| SepA, the major extracellular protein of Shigella flexneri: autonomous secretion and involvement in tissue invasion | Q48072701 | ||
| Chromosomal and plasmid-encoded factors of Shigella flexneri induce secretogenic activity ex vivo | Q34482917 | ||
| Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates. | Q34809879 | ||
| Human milk immunoglobulin A antibodies to Shigella virulence determinants. | Q35096605 | ||
| Antigen dependent and independent mechanisms that sustain serum antibody levels | Q35134698 | ||
| Protection of Monkeys Against Experimental Shigellosis with Attenuated Vaccines. | Q35163992 | ||
| Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides | Q35335585 | ||
| Persistence of local cytokine production in shigellosis in acute and convalescent stages. | Q35380946 | ||
| Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains | Q35455031 | ||
| Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers | Q35523144 | ||
| Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. | Q35528270 | ||
| Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit | Q35598035 | ||
| Broadly protective Shigella vaccine based on type III secretion apparatus proteins | Q35805439 | ||
| O-Acetylation in the O-specific polysaccharide isolated from Shigella flexneri serotype 2a | Q35828313 | ||
| The Global Enteric Multicenter Study (GEMS) of diarrheal disease in infants and young children in developing countries: epidemiologic and clinical methods of the case/control study | Q36412034 | ||
| Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. | Q36422508 | ||
| Live-attenuated Shigella vaccines | Q36689023 | ||
| Shigella's ways of manipulating the host intestinal innate and adaptive immune system: a tool box for survival? | Q36703588 | ||
| Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road | Q36844719 | ||
| Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides. | Q36966451 | ||
| Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. | Q36989971 | ||
| Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp | Q37010733 | ||
| Phenotypic and functional heterogeneity of human memory B cells | Q37079426 | ||
| Retinoic acid-dependent regulation of immune responses by dendritic cells and macrophages | Q37096952 | ||
| Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates | Q37120727 | ||
| Protection of Monkeys Against Experimental Shigellosis with a Living Attenuated Oral Polyvalent Dysentery Vaccine | Q37387409 | ||
| Intestinal dendritic cells: their role in bacterial recognition, lymphocyte homing, and intestinal inflammation | Q37707264 | ||
| Cross-presentation by dendritic cells | Q38025870 | ||
| The Shigella human challenge model | Q38035961 | ||
| New concepts in the generation and functions of IgA. | Q38056035 | ||
| Safety and colonization of two novel VirG(IcsA)-based live Shigella sonnei vaccine strains in rhesus macaques (Macaca mulatta) | Q38294092 | ||
| Effects of backbone substitutions on the conformational behavior of Shigella flexneri O-antigens: implications for vaccine strategy | Q38339729 | ||
| Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial | Q38879736 | ||
| Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants | Q39044644 | ||
| Diarrheal disease during Operation Desert Shield | Q39090383 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| P304 | page(s) | 245-255 | |
| P577 | publication date | 2013-02-19 | |
| P1433 | published in | Nature Reviews Gastroenterology & Hepatology | Q2108255 |
| P1476 | title | Progress and pitfalls in Shigella vaccine research | |
| P478 | volume | 10 |
| Q57929967 | A Novel Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental Challenge |
| Q91644990 | A bivalent vaccine confers immunogenicity and protection against Shigella flexneri and enterotoxigenic Escherichia coli infections in mice |
| Q64996406 | A murine model of diarrhea, growth impairment and metabolic disturbances with Shigella flexneri infection and the role of zinc deficiency. |
| Q85333357 | A novel protein-based subunit Shigella vaccine candidate |
| Q39093233 | An Overview of Structural Features of Antibacterial Glycoconjugate Vaccines That Influence Their Immunogenicity. |
| Q38284501 | An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children |
| Q37668395 | An update on vaccines against Shigella |
| Q28066540 | Bacterial genome engineering and synthetic biology: combating pathogens |
| Q93001883 | Bacteriophage Therapy Testing Against Shigella flexneri in a Novel Human Intestinal Organoid-Derived Infection Model |
| Q38286609 | Bacteriophage administration significantly reduces Shigella colonization and shedding by Shigella-challenged mice without deleterious side effects and distortions in the gut microbiota |
| Q38776163 | Characterization of a multicomponent live, attenuated Shigella flexneri vaccine |
| Q37335984 | Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine. |
| Q37123743 | Characterization of intracellular growth regulator icgR by utilizing transcriptomics to identify mediators of pathogenesis in Shigella flexneri |
| Q58697147 | Chemical Synthesis of Rare, Deoxy-Amino Sugars Containing Bacterial Glycoconjugates as Potential Vaccine Candidates |
| Q37067264 | Circulating Gut-Homing (α4β7+) Plasmablast Responses against Shigella Surface Protein Antigens among Hospitalized Patients with Diarrhea |
| Q92487093 | Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human |
| Q35896237 | Combination vaccines against diarrheal diseases |
| Q59138059 | Cross-Protective Whole-Cell Vaccine With a Truncated O-Polysaccharide Chain |
| Q58277163 | Determination ofShigella flexneriby a Novel Fluorescent Aptasensor |
| Q37643320 | Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine. |
| Q40552716 | Development of recombinant vaccine candidate molecule against Shigella infection |
| Q40622945 | Efficient Iterative Synthesis of O-Acetylated Tri- to Pentadecasaccharides Related to the Lipopolysaccharide of Shigella flexneri Type 3 a through Di- and Trisaccharide Glycosyl Donors |
| Q36764372 | Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects |
| Q37633069 | Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study |
| Q33686643 | Genomic analysis of the emergence of 20th century epidemic dysentery. |
| Q34068059 | Gut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans |
| Q91166657 | Highly homogenous tri-acylated S-LPS acts as a novel clinically applicable vaccine against Shigella flexneri 2a infection |
| Q40120134 | Immunofluorescence Analysis of Stress Granule Formation After Bacterial Challenge of Mammalian Cells. |
| Q28537818 | Impact of dynasore an inhibitor of dynamin II on Shigella flexneri infection |
| Q30252225 | Impact of rotavirus vaccine introduction and post-introduction etiology of diarrhea requiring hospital admission in Haydom, Tanzania, a rural African setting |
| Q38636542 | Injection of T3SS effectors not resulting in invasion is the main targeting mechanism of Shigella toward human lymphocytes |
| Q37720658 | Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes |
| Q39202268 | Linear synthesis of the branched pentasaccharide repeats of O-antigens from Shigella flexneri 1a and 1b demonstrating the major steric hindrance associated with type-specific glucosylation |
| Q38198766 | Management of acute infectious diarrhea for children living in resource-limited settings. |
| Q100731064 | NAIP-NLRC4-deficient mice are susceptible to shigellosis |
| Q41609325 | Programmed chemo-enzymatic synthesis of the oligosaccharide component of a carbohydrate-based antibacterial vaccine candidate |
| Q85770531 | Recombinant expressed vector pET32a (+) S constructed by ligation independent cloning |
| Q48669093 | Recommendations regarding the development of combined enterotoxigenic Eschericha coli and Shigella vaccines for infants |
| Q39056494 | Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study |
| Q26860903 | Salmonella, Shigella, and yersinia |
| Q26771364 | Shigella IpaH Family Effectors as a Versatile Model for Studying Pathogenic Bacteria |
| Q37477191 | Shigella Vaccine Development: Finding the Path of Least Resistance |
| Q36062710 | Shigella flexneri serotype 1c derived from serotype 1a by acquisition of gtrIC gene cluster via a bacteriophage. |
| Q34202171 | Shigella isolates from the global enteric multicenter study inform vaccine development |
| Q35221181 | Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection |
| Q92968788 | Shigella-mediated immunosuppression in the human gut: subversion extends from innate to adaptive immune responses |
| Q56383780 | Shigellosis |
| Q34518265 | Status of vaccine research and development for Shigella |
| Q38648228 | Summary of workshop "global burden of diarrheal diseases among children in developing countries: Incidence, etiology, and insights from new molecular diagnostic techniques". |
| Q92404815 | Synthetic carbohydrate-based vaccines: challenges and opportunities |
| Q30966045 | The association between diurnal temperature range and childhood bacillary dysentery |
| Q38263749 | The bacterial pathogen-ubiquitin interface: lessons learned from Shigella |
| Q38753453 | The genomic signatures of Shigella evolution, adaptation and geographical spread |
| Q64244950 | Vaccination With Mouse Dendritic Cells Loaded With an IpaD-IpaB Fusion Provides Protection Against Shigellosis |
| Q41263122 | Whole genome analysis to detect potential vaccine-induced changes on Shigella sonnei genome. |
Search more.